STAT3 Therapeutics is a pre-clinical, oncology company dedicated to developing and commercializing drugs that target the activated STAT3 molecule. Our unique approach arrests the activity of the STAT3 dimer using a cyclic decoy that binds to the molecule in a way that is both specific and impactful without significant toxic side effects. STAT3 activation increases cancer cell proliferation, promotes immunosuppression, and appears in over 70% of all human cancers. STAT3 plays an important regulatory role in a variety of cancers and also has been indicated as a factor in non-cancer indications such as autoimmune diseases. With this in mind, STAT3 Therapeutics approach to drug development has broad applicability. Our initial focus on head and neck cancers where 95% of all such cancers shows hyperactivated STAT3 present.